Navigation Links
HIIP- A Novel Inhaled Insulin Delivery System As An Alternative To Injectable Insulin Therapy

The disease burden of diabetes continues to grow and currently affects more that 18 million Americans and their families. These data emphasize a need for alternative diabetes therapies with earlier more physiologic use of insulin.//

The delivery of insulin by the lung may provide an attractive alternative for many patients with diabetes. However, alternative insulin delivery systems must meet certain pharmacokinetic and glucodynamic requirements to reach maximum utility. Specifically, the dose-response characteristics of inhaled insulin should be similar to those of injectable insulins, like human regular insulin or fast-acting insulin analogs such as insulin lispro. A recent study, published in the October issue of Diabetes Care, evaluated the key performance features of a novel inhaled insulin delivery system -- human insulin inhalation powder (HIIP) -- based on AIR particle technology and its relative biopotency compared with subcutaneous (SC) insulin lispro.

The researchers enrolled 20 healthy, nonsmoking, male or female subjects (aged 29.6 years, BMI 23.2 kg/m2) with normal forced vital capacity and forced expiratory volume in an open-label, randomized, seven-period, euglycemic glucose clamp, cross-over trial. Each subject received up to 4 single doses of HIIP and 3 doses of SC lispro from 5 to 18 days apart.

HIIP demonstrated a similar rapid onset but an extended time exposure and a prolonged duration of effect compared with SC lispro. While the time-action profile was longer for HIIP than for SC lispro, both treatments showed rapid initial absorption and similar overall PK exposure and GD effect.

Remarkably, in the current study not a single episode of cough was registered, suggesting an excellent tolerability of the inhaled insulin when formulated by the AIR particle technology. However, the authors warn that this result needs to be confirmed in much larger phase 3 trials. Taken together, these results suppor t the potential utility of inhaled insulin as an alternative to insulin injections. Because the fear of injections is a frequent cause for delaying appropriate care in patients with type 2 diabetes, inhaled insulin may provide a treatment that delivers effective doses of insulin in a less threatening, more satisfying manner, potentially resulting in improved patient compliance and better outcomes.
'"/>




Related medicine news :

1. Novel "CYCLOSPORINE CAPSULE FORMULATION" to be launched
2. Novel biopsy technique for prostate cancer
3. Novel computer model for breast cancer
4. Novel research on liver cancer
5. Novel way to fight cancer
6. Novel test for bowel cancer
7. Novel Anti-Neutrophilic Effect produced by Salmeterol in mild asthma patients
8. Novel Therapy for Chronic Problem
9. Blood Sugar Kept In Control By Novel Protein
10. Novel antibiotic dressing developed for improved wound healing
11. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/10/2016)... ... February 10, 2016 , ... 10 Best Water is excited to ... water brand owners that topped the list as a result of their commitment to ... premier brand was Tibet 5100, a top notch water company that specializes in providing ...
(Date:2/10/2016)... ... February 10, 2016 , ... Intalere’s 2016 ... more than 200 of the country’s top healthcare executives to share insights on ... benefit of the Forum is the provider-centric perspective, experience, expertise and strategy shared ...
(Date:2/10/2016)... ... February 10, 2016 , ... Armune BioScience ... across their network of laboratory service centers across the country. Launched in April of ... in the detection of prostate cancer. Apifiny order volume exceeded 3,000 tests in 2015. ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... the Ohio Safety Congress and Expo event March 9-11, 2016. Hosted by Ohio's ... Convention Center. , As the longest running and largest worker's compensation event ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... February 26th: Amateur & Professional Divisions - Time: 7:00pm – 10:00pm | ... | Ticket Prices $30, Social Media: http://www.USPoleSportsFed.org , Facebook: http://www.facebook.com/uspolesportsfederation ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)...  Resolve Therapeutics, LLC, a clinical stage biopharmaceutical ... treatment of lupus and Sjogrens syndrome, today announced ... study in patients with systemic lupus erythematosus (SLE) ... --> --> Data from a ... of RSLV-132 in 32 subjects with SLE demonstrate ...
(Date:2/10/2016)... 2016 Immune Pharmaceuticals Inc. (NASDAQ: IMNP ... it has filed a patent application directed to the ... --> --> The new ... Ceplene (histamine dihydrochloride) in combination with immune checkpoint inhibitors. ... efficacy of Ceplene and IL-2 therapy in patients with ...
(Date:2/10/2016)... A Worldwide Clinical Trials expert will present at ... Plaza in London , 24-25 February 2016. ... advances for late phase research on Wednesday, 24 Feb at ... director of project management at Worldwide, will focus on how ... standards in late phase research. --> ...
Breaking Medicine Technology: